DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-G-G-T-G-A-A-G-M5C-G-A-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC)
Hepatitis B
GlaxoSmithKlinenucleic_acidPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Hepatitis B cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Entecavir Sun Yat-sen University | Phase 4 | BBB |
Lamivudine Fudan University | Phase 4 | BBB |
tenofovir Ruijin Hospital | Phase 4 | BB |
TENOFOVIR BIS(ISOPROPYLOXYCARBONYLOXYMETHYL) ESTER West China Hospital | Phase 4 | BB |
Hepatitis B Virus Vaccine Eunice Dube | Phase 4 | BB |
View all 45 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →